Tacita Capital Inc Gilead Sciences, Inc. Transaction History

Tacita Capital Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$73.27 - $83.09 $16,485 - $18,695	-225 Reduced 19.07%	955 $77,000
Q3 2023 Nov 13, 2023	BUY	$73.94 - $80.67 $16,636 - $18,150	225 Added 23.56%	1,180 $88,000
Q4 2022 Feb 09, 2023	SELL	$62.32 - $89.47 $2,804 - $4,026	-45 Reduced 4.5%	955 $82,000
Q2 2022 Aug 12, 2022	BUY	$57.72 - $65.01 $39,538 - $44,531	685 Added 217.46%	1,000 $62,000
Q1 2022 May 12, 2022	BUY	$57.92 - $72.58 $18,244 - $22,862	315 New	315 $19,000
Q2 2021 Aug 12, 2021	SELL	$63.47 - $69.35 $9,520 - $10,402	-150 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$60.0 - $68.46 $45,000 - $51,344	-750 Reduced 83.33%	150 $10,000
Q4 2020 Feb 17, 2021	BUY	$56.65 - $64.55 $50,985 - $58,095	900 New	900 $52,000

1,893

1.02B

12M

9.04M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Tacita Capital Inc, based on Form 13F filings with the SEC.

Stay updated on Tacita Capital Inc with notifications on news.